Last reviewed · How we verify

NCT03536195: HEMOSTIR

Impact of Renal Replacement Therapy on Coagulation Profile of Patients with Acute Renal Failure

Completed Last updated 24 March 2025
What this trial tests

trial in Acute Renal Failure in 14 participants. Completed in 23 November 2021.

Timeline
18 August 2018
Primary endpoint
23 November 2021
23 November 2021

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusCompleted
Study typeOBSERVATIONAL
Enrollment14
Start date18 August 2018
Primary completion23 November 2021
Estimated completion23 November 2021
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

18 and older, any sex, with Acute Renal Failure or Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Renal failure and high plasmatic level of urea have been associated with an increased risk of hemorrhage in surgical patients. There is only sparse data on the impact of renal replacement therapy on homeostatic parameters. The aim of this study is to describe potential changes in homeostatic parameters before and after renal replacement therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Renal Failure

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03536195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing